North America Radiopharmaceutical Theranostics Market Forecast to 2028
North America Radiopharmaceutical Theranostics Market Forecast to 2028 – Regional Analysis – by Product Type [Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers], Radioisotope [Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others], Source (Nuclear Reactors and Cyclotrons), Application [Targeted Therapeutic (Rx) and Companion Diagnostic (CDx)], Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Application in Treatment of Cardiovascular Disorders
Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.
As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.
North America Radiopharmaceutical Theranostics Market Overview
The North America radiopharmaceutical theranostics market is segmented into US, Canada, and Mexico. The US is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.
North America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
North America Radiopharmaceutical Theranostics Market Segmentation
The North America radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the North America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.
Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.
Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to The Research Team’ research, the North America radiopharmaceutical theranostics market was valued at US$ 795.88 million in 2022 and is expected to reach US$ 1,529.95 million by 2028, registering a CAGR of 11.5% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the North America radiopharmaceutical theranostics market expansion.
The most common types of cancer are breast, lung, colon, rectum, and prostate. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.
According to the American Cancer Society’s 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.
Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall market growth. This is expected to drive the North America radiopharmaceutical theranostics market during the forecast period.
On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of North America radiopharmaceutical theranostics market.
Based on product type, the North America radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 41.0% market share in 2022, amassing US$ 326.05 million. It is projected to garner US$ 648.92 million by 2028 to expand at 12.2% CAGR during 2022–2028.
Based on radioisotope, the North America radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 22.2% market share in 2022, amassing US$ 176.41 million. It is projected to garner US$ 361.06 million by 2028 to expand at 12.7% CAGR during 2022–2028.
Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 61.5% market share in 2022, amassing US$ 489.69 million. It is projected to garner US$ 997.72 million by 2028 to expand at 12.6% CAGR during 2022–2028.
Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 61.7% market share in 2022, amassing US$ 491.01 million. It is projected to garner US$ 957.60 million by 2028 to expand at 11.8% CAGR during 2022–2028.
Based on indication, the North America radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 62.6% market share in 2022, amassing US$ 497.94 million. It is projected to garner US$ 991.23 million by 2028 to expand at 12.2% CAGR during 2022–2028.
Based on end user, the North America radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 38.0% market share in 2022, amassing US$ 302.22 million. It is projected to garner US$ 572.70 million by 2028 to expand at 11.2% CAGR during 2022–2028.
Based on country, the North America radiopharmaceutical theranostics market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 71.4% share of North America radiopharmaceutical theranostics market in 2022. It was assessed at US$ 568.44 million in 2022 and is likely to hit US$ 1,121.51 million by 2028, exhibiting a CAGR of 12.0% during the forecast period.
Key players dominating the North America radiopharmaceutical theranostics market are Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences among others.
In Oct 2022, NuView Life Sciences Provides Corporate Update On NV-VPAC1 Theranostic for Breast Cancer. In Feb 2022, Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America radiopharmaceutical theranostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America radiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook in regional market coupled with the factors driving the market, as well as those hindering it.
o Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Research Team Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Radiopharmaceutical Theranostics Market – by Product Type
1.3.2 North America Radiopharmaceutical Theranostics Market – by Radioisotope
1.3.3 North America Radiopharmaceutical Theranostics Market – by Source
1.3.4 North America Radiopharmaceutical Theranostics Market – by Application
1.3.5 North America Radiopharmaceutical Theranostics Market – by Indication
1.3.6 North America Radiopharmaceutical Theranostics Market – by End User
1.3.7 North America Radiopharmaceutical Theranostics Market – by Country
2. Radiopharmaceutical Theranostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Radiopharmaceutical Theranostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Radiopharmaceutical Theranostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidence of Cancer
5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis
6. Radiopharmaceutical Theranostics Market – North America Analysis
6.1 North America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
7. North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Product Type
7.1 Overview
7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
7.2.1 Positron Emission Tomography (PET) Tracers
7.2.1.1 Overview
7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.2 Beta Emitters
7.2.2.1 Overview
7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.3 Alpha Emitters
7.2.3.1 Overview
7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Radiopharmaceutical Theranostics Market Analysis – by Radioisotope
8.1 Overview
8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
8.2.1 Technetium-99
8.2.1.1 Overview
8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.2 Gallium-68
8.2.2.1 Overview
8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.3 Iodine-131
8.2.3.1 Overview
8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4 Iodine-123
8.2.4.1 Overview
8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.5 Fluorine-18 (18F)
8.2.5.1 Overview
8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.6 Yttrium 90 (Y-90)
8.2.6.1 Overview
8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.7 Lutetium (LU) 177
8.2.7.1 Overview
8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.8 Copper (CU) 67
8.2.8.1 Overview
8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.9 Copper (CU) 64
8.2.9.1 Overview
8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.10 Others
8.2.10.1 Overview
8.2.10.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Radiopharmaceutical Theranostics Market Analysis – by Source
9.1 Overview
9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
9.2.1 Nuclear Reactors
9.2.1.1 Overview
9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.2 Cyclotrons
9.2.2.1 Overview
9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Radiopharmaceutical Theranostics Market Analysis – by Application
10.1 Overview
10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
10.2.1 Targeted Therapeutic (Rx)
10.2.1.1 Overview
10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10.2.2 Companion Diagnostic (CDx)
10.2.2.1 Overview
10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11. North America Radiopharmaceutical Theranostics Market Analysis – by Indication
11.1 Overview
11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
11.2.1 Oncology
11.2.1.1 Overview
11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.2 Neurology
11.2.2.1 Overview
11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.3 Cardiology
11.2.3.1 Overview
11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.4 Others
11.2.4.1 Overview
11.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12. North America Radiopharmaceutical Theranostics Market Analysis – by End User
12.1 Overview
12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
12.2.1 Hospitals
12.2.1.1 Overview
12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.2 Diagnostic Imaging Centers
12.2.2.1 Overview
12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.3 Academic & Research Institutes
12.2.3.1 Overview
12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.4 Others
12.2.4.1 Overview
12.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13. North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Country Analysis
13.1 North America: Radiopharmaceutical Theranostics Market
13.1.1 Overview
13.1.1.1 United States: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.1.1 Overview
13.1.1.1.2 United States: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.1.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.1.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.1.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.1.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.1.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.1.2 Canada: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.2.1 Overview
13.1.1.2.2 Canada: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.1.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.1.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.1.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.1.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.1.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.1.3 Mexico: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.3.1 Overview
13.1.1.3.2 Mexico: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.1.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.1.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.1.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.1.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.1.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.1.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
14. Radiopharmaceutical Theranostics Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
14.3 Inorganic Growth Strategies
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Bayer AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 GE HealthCare Technologies Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Curium
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Lantheus Medical Imaging, Inc.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Telix Pharmaceuticals Ltd.
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Cardinal Health Inc
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Advanced Accelerator Applications S.A.
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Jubilant Radiopharma
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Theragnostics
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 NuView Life Sciences
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Research Team
16.2 Glossary of Terms
LIST OF TABLES
Table 1. United States Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. United States Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 3. United States Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 4. United States Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. United States Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 6. United States Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 20. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 21. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Radiopharmaceutical Theranostics Market Segmentation
Figure 2. North America Radiopharmaceutical Theranostics Market, by Country
Figure 3. North America Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. US Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. North America Experts’ Opinion
Figure 8. North America Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 9. North America Radiopharmaceutical Theranostics Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. North America Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Positron Emission Tomography (PET) Tracers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Beta Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Alpha Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 15. Technetium-99: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Gallium-68: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Iodine-131: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Iodine-123: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Fluorine-18 (18F): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Yttrium 90 (Y-90): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Lutetium (LU) 177: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Copper (CU) 67: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Copper (CU) 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Others: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. North America Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 26. Nuclear Reactors: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Cyclotrons: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. North America Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 29. Targeted Therapeutics (Rx): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Companion Diagnostics (CDx): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. North America Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 32. Oncology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Neurology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Cardiology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Others: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. North America Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 37. Hospitals: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Diagnostic Imaging Centers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Academic & Research Institutes: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Others: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. North America: Radiopharmaceutical Theranostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 42. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 43. United States: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Canada: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Mexico: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Growth Strategies in the Radiopharmaceutical Theranostics Market
The List of Companies – North America Radiopharmaceutical Theranostics Market
1. Bayer AG
2. GE Healthcare Technologies Inc.
3. Curium
4. Lantheus Medical Imaging, Inc.
5. Telix Pharmaceuticals Ltd.
6. Cardinal Health Inc.
7. Advanced Accelerator Applications S.A
8. Jubilant Radiopharma
9. Theragnostics
10. NuView Life Sciences
You must be logged in to post a review.
Reviews
There are no reviews yet.